down arrow

Emcure Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE168P01015
  • NSEID: EMCURE
  • BSEID: 544210
INR
909.70
3.9 (0.43%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 32.99 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Emcure Pharmaceuticals Ltd stock-summary
stock-summary
Emcure Pharmaceuticals Ltd
Mid Cap
Pharmaceuticals & Drugs
Emcure Pharmaceuticals Limited was originally incorporated as `Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to `Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.
Company Coordinates stock-summary
Icon
No Company Details Available
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 189.10 Cr
Number of Shares
18.91 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
08-Jul-2024
18.91
189.10
7946231
10
Public Issue
07-Mar-2024
18.12
181.15
300000
10
Issued under ESOP Scheme
22-Mar-2016
18.09
180.85
135639087
10
Bonus Issue
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 20 Schemes (3.1%)

FIIs

Held by 46 FIIs (3.05%)

Promoter with highest holding

Satish R Mehta (39.8%)

Highest Public shareholder

Bc Investments Iv Limited (8.68%)

Individual Investors Holdings

5.14%

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
 
Icon
No Data Available
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,963 Cr
(Quarterly Results - Dec 2024)
Net Profit:
154 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 17,237 Cr (Mid Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.23

stock-summary
Return on Equity

12.27%

stock-summary
Price to Book

4.17